Language

Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

DRUG PLAN EXPANDED

Released on July 10, 2001

The Saskatchewan Drug Plan expanded coverage to add 60 new products as of

July 1st.



Most of the products added are new strengths or generic versions of drugs

that are already covered.



One of these is the first generic brand of warfarin. Warfarin is used to

treat clotting disorders and is commonly prescribed to patients who have

had a stroke. It will be considered interchangeable with the currently

listed Coumadin® brand.



Two drugs, raloxifene and lopinavir/ritonavir have been given Exception

Drug Status (EDS). EDS drugs are approved for patients who, based on

scientific evidence, are most likely to benefit. Raloxifene (Evista®) will

be approved for the treatment of osteoporosis in women unable to tolerate

or who do not respond to bisphosphonates after treatment for one year.

Lopinavir/ritonavir (Kaletra®) will be approved for the management of HIV

disease. It should be used under the direction of a specialist in

infectious diseases.



"The independent drug review determines the benefits of new drugs to

patients and their value to the healthcare system and it ensures the

Saskatchewan Drug Plan is continuously updating treatment options to

improve the health of Saskatchewan residents," Health Minister John Nilson

said.



Six drugs were reviewed but were not approved for coverage. One of the

drugs not recommended by the Saskatchewan Formulary Committee (SFC) is

riluzole, also known as Rilutek®, for the treatment of ALS (Lou Gehrig's

Disease). The committee found the clinical benefit of the drug did not

justify the cost. Clinical studies did not demonstrate an effect on

quality of life.



The Saskatchewan Prescription Drug Plan currently covers about 3,400

products and assists approximately 111,000 families each year. The drug

plan paid out approximately $96 million in benefits to more than 184,500

residents in 2000.



The drug plan assists with drug costs for families with low income,

families with high drug costs, or those with a combination of the two. The

Saskatchewan Government will invest $115 million for Saskatchewan Drug Plan

expenditures in 2001/02. This is a 16 percent increase from the previous

year.



-30-



For more information, contact:



Myrna Stark Leader

Health

Regina

Phone: (306) 787-4083

We need your feedback to improve saskatchewan.ca. Help us improve